Tradestie Institutional Equity Comparison Engine

ZBIO vs LQDA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LQDA Overall Edge

LQDA Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Liquidia Corporation Common Stock (LQDA) driven by superior Valuation, Growth & Margin, Momentum & Technical while ZBIO counters with relative strength in Options & Structure. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus LQDA at 16.4x Forward P/E and 47.1% operating margin (+314.6% YoY). In options structure, ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against LQDA sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LQDA
ZBIO N/M vs LQDA 16.4x Fwd P/E
Growth & Margin Winner LQDA
Op Margin -2747.5% vs 47.1% ยท YoY -100.0% vs +314.6%
Momentum & Technical Winner LQDA
1Y -21.7% vs +109.2% ยท 52W Pos 46% vs 48%
Options & Structure Winner ZBIO
CONSOLIDATION (13th %ile IV) vs BREAKDOWN (10th %ile IV)
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
LQDA NASDAQ
Liquidia Corporation Common Stock
Pharmaceutical Preparations
$56.37
-1.81% 1D
Market Cap $5.2B
1M Return +64.1%
1Y Return +109.24%
Forward P/E 16.4x
Unified AI Score
25.6 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZBIO -21.68% LQDA +109.24% Spread: +130.92 pp (LQDA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ZBIO Revenue LQDA Revenue ZBIO Op. Margin LQDA Op. Margin Margin Edge
FY2019 N/A $10M N/A -580.1% LQDA
FY2020 N/A $0M N/A -7989.0% LQDA
FY2021 N/A $10M N/A -263.0% LQDA
FY2022 N/A $20M N/A -243.3% LQDA
FY2023 $50M $20M -74.3% -419.6% ZBIO
FY2024 $10M $10M -3277.8% -866.6% LQDA
FY2025 $10M $160M -3830.6% -32.5% LQDA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZBIO (3) vs LQDA (7)
Institutional Metric ZBIO LQDA Criterion Row Winner
Market Capitalization Scale $1.9B $5.2B Larger Scale LQDA
Trailing P/E Ratio Valuation N/M 13.8x Lower Multiple LQDA
Forward P/E Ratio Valuation N/M 16.4x Lower Multiple LQDA
Revenue Growth (YoY) Growth -100.0% +314.6% Higher Growth LQDA
Operating Margin (TTM) Profitability -2747.5% 47.1% Higher Margin LQDA
Net Profit Margin Profitability 0.0% -15.2% Higher Margin ZBIO
Return on Equity (ROE) Capital Efficiency -265.1% 131.8% Higher ROE LQDA
52-Week Range Position Momentum 46% ($14โ€“$45) 48% ($22โ€“$94) Stronger Trend LQDA
Beta / 30D Volatility Risk Regime 1.16ฮฒ ยท 59% Vol 0.99ฮฒ ยท 77% Vol Lower Realized Risk ZBIO
Unified Institutional Score Composite Signal 49.4 / 100 (HOLD) 25.6 / 100 (SELL) Higher Composite ZBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZBIO vs LQDA Buy Guide
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LQDA BREAKDOWN
81d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live LQDA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZBIO nor LQDA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.